Target Drug Therapy for Pancreatic Tumors

Pancreatic cancer is an aggressive disease in which malignant cells form in the tissues of the pancreas, a long and flat gland located behind the stomach that helps with digestion and blood sugar regulation.

According to the National Cancer Institute pancreatic cancer accounts for nearly 8% of all cancer deaths because of difficulty in detecting early results in low survival rate.

Immune-boosting Compound Enhances Immunotherapy Against Pancreatic Cancer
An immune-boosting compound increases the efficacy of immunotherapy against pancreatic cancer. The new drug promotes the killing of the cancer cells, resulting in the reduction of tumor size and longer life span.

‘New drug AT7519 for treating pancreatic tumors.’

A pre-clinical study conducted in Moffitt Cancer Center and published in Clinical Cancer Research identifies a novel drug that effectively prevents mutant KRAS gene to cause pancreatic tumors.

"We discovered a link between hyperactivation of the CDK protein and mutant KRAS addiction, and we exploited this link preclinically to counter mutant KRAS-driven pancreatic cancer, warranting clinical investigation in patients afflicted with this deadly disease," said Sebti, who is also the Lacy Family Chair in Cancer Research at Massey and a professor of pharmacology and toxicology at the VCU School of Medicine.

This is considered as a new avenue to combat an aggressive form of pancreatic cancer with very poor prognosis mainly due to its resistance to conventional therapies.

Gene Expression Patterns in Pancreatic Tumor Cells Identified in MGH Study
New research reveals that analysis of circulating tumor cells in a mouse model of pancreatic cancer identified distinct patterns of gene expression.

Mapping out the blueprint of pancreatic cancer cells through global phosphoproteomics is the first step in this study to know about the difference in addicted and non-addicted tumors at the phosphoprotein level and also discovered two proteins CDK1 and CDK2 indicate cells addicted to mutant KRAS.

Additionally, they analyzed a comprehensive database from the Broad Institute of MIT and Harvard to discover that CDK1 and CDK2 as well as CDK7 and CDK9 proteins were associated with mutant KRAS-addicted tumors.

Later they evaluated the ability of a library of 294 FDA drugs to selectively kill mutant KRAS-addicted cancer cells over non-KRAS-addicted cancer cells in the lab and discovered the most effective drug in preclinical experiments is AT7519, an inhibitor of CDK1, CDK2, CDK7 and CDK9.

These findings are validated by AT7519 suppressing the growth of xenograft cells from five mutant KRAS pancreatic cancer patients who relapsed on chemotherapy and/or radiation therapies.

Novel Nuclear Medicine Method Effectively Detects Neuroendocrine Tumors
New nuclear medicine procedure showed promise for better detection of neuroendocrine tumors, stated study.

We need to translate these findings in humans to see a positive response in pancreatic cancer addicted to mutant KRAS and can also be used for colorectal and non-small cell lung cancer patients where mutations in KRAS are prevalent.

Source-Medindia